Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Selexipag vs Uptravi in Healthy Subjects Under Fed Conditions
NCT06932198Phase 1Completed
- Sponsor
- Humanis
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Humanis. Primary endpoints: Maximum Concentration at 72 hours and Area Under the Curve from time 0 to last collection time t at 72 hours. Started Jan 2025; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06932198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932198.